Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VRTX News 13 December 2025 - 22 January 2026

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares rose 4.31% to $461.14, extending gains for a third session with trading volume above the 50-day average. The company will report fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call. Director Bruce I. Sachs received 107.088 deferred stock units, according to a Jan. 15 regulatory filing.
22 January 2026
···
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis+1 The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers. Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which
2 January 2026
······
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the week of December 22–26, 2025 with a familiar setup for biotech investors: a cash-rich market leader in cystic fibrosis (CF), a pipeline that could meaningfully diversify revenue over the next 12–24 months, and a stock that can move quickly on headlines—even when broader markets are quiet. The difference this time is the calendar. U.S. equities trading will be compressed by Christmas, with an early close on Wednesday, Dec. 24 (1:00 p.m. ET) and markets closed Thursday, Dec. 25. That tends to thin liquidity and can magnify price swings—up or down—on even modest
22 December 2025
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF) business that has dominated its revenue for more than a decade? VRTX shares most recently closed at $456.20 on Friday, Dec. 19, up 1.97% in that session. StockAnalysis Below is the current news, forecasts, and market analysis shaping Vertex stock as of Dec. 20, 2025, including the latest on Casgevy’s pediatric data, Journavx’s commercial ramp, and a kidney-disease pipeline that
21 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday, December 19, 2025, on a strong note and then stayed relatively steady in after-hours trading—setting up a familiar “what happens next?” question for investors heading into the final full week before year-end. Below is a detailed rundown of what moved VRTX today, what the after-hours tape is saying, what analysts are forecasting right now, and the key catalysts to watch before the next U.S. market open (Monday, December 22, 2025). VRTX after the bell: where the stock closed and how it traded after hours VRTX rose 1.97% in the regular session to close
20 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the Monday, December 15, 2025 U.S. market open with investors weighing a familiar mix: a dominant cystic fibrosis (CF) franchise that funds the story, and a fast-expanding pipeline that’s increasingly driving the debate about what Vertex should be worth next. The stock ended the last regular session (Friday, Dec. 12) at $452.04, up 1.37% on the day, extending a three-session winning streak and outperforming a down market. MarketWatch At the same time, shares remain about 13% below the 52-week high of $519.68 set in March, reflecting how much scrutiny remains on the pace
15 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Dec. 12, 2025 (U.S. market close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday at $452.04, extending a late-week rebound after a choppy start to the week. The stock’s intraday range on Friday stretched from $442.94 to $455.99 on volume of about 1.62 million shares, as biotech investors weighed fresh pipeline headlines, Wall Street price-target moves, and a shifting macro backdrop following the Federal Reserve’s latest rate decision. MarketWatch+1 Below is a detailed, publication-ready breakdown of all notable VRTX news from the past several days, the latest analyst forecasts, and what could matter most for next week’s trading. VRTX stock
13 December 2025
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop